Table 2.
aMCI (n = 53) | naMCI (n = 26) | SCD (n = 38) | |
---|---|---|---|
0 | 26.4% | 40.7% | 41.2% |
1 | 26.4% | 33.3% | 35.3% |
2 | 18.9% | 22.2% | 20.6% |
3 | 24.5% | 3.7% | 2.9% |
4 | 3.8% | 0% | 0% |
Percentage of clinical groups with 0–4 pathological biomarkers.
aMCI (n = 53) | naMCI (n = 26) | SCD (n = 38) | |
---|---|---|---|
0 | 26.4% | 40.7% | 41.2% |
1 | 26.4% | 33.3% | 35.3% |
2 | 18.9% | 22.2% | 20.6% |
3 | 24.5% | 3.7% | 2.9% |
4 | 3.8% | 0% | 0% |
Percentage of clinical groups with 0–4 pathological biomarkers.